Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis
Immunology · 2023-11 · 170 (3) · 439-451
DOI: 10.1111/imm.13683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2023-08. Verfasst von Jingjing Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Ferroptosis, Colonic Neoplasms, Immunotherapy, Deubiquitinating Enzymes. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Huai'an Natural Science Research Program, Innovation Key Talent Program of Huai'an First People's Hospital.
Abstract (Originalsprache)
A substantial number of colon cancer patients do not benefit from immunotherapy using programmed cell death 1 (PD1) antibodies. Therefore, combination therapy drugs are required to improve the efficacy of colon cancer immunotherapy. Recent studies have shown that deubiquitinases are negative regulators of anti‐tumour immunity. In the present study, we investigated the effect of the deubiquitinase inhibitor PR‐619 in combination with anti‐PD1 for the treatment of colorectal cancer. The results revealed that co‐treatment with PR‐619 and anti‐PD1 significantly inhibited tumour growth in tumour‐bearing BALB/c mice compared to monotherapy with a single drug. In addition, PR‐619/anti‐PD1 combined therapy inhibited cell proliferation, promoted cell apoptosis, induced intratumor infiltration of CD8 + T cells, and enhanced the release of anti‐tumour cytokines. Moreover, PR‐619 induced ferroptosis in colon cancer cells, thereby inducing the release of damage‐associated molecular patterns that triggered anti‐tumour immunity. Finally, we discovered that PR‐619 could degrade the GPX4 protein, the high expression of which was associated with poor prognosis and blocked CD8 + T cells infiltration in colon cancer. In conclusion, PR‐619 may potentiate immunotherapy by inducing ferroptosis, and thereby promoting CD8 + T cells‐mediated anti‐tumour immunity, providing a potential strategy for colon cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
- Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
ORCID-Profile: Bin Wei
Förderung
- National Natural Science Foundation of China
- Huai'an Natural Science Research Program
- Innovation Key Talent Program of Huai'an First People's Hospital
- Young Innovative Talent Program of Huai'an First People's Hospital
Zitieren
APA
Wu, J., Liu, C., Wang, T., Liu, H., & Wei, B. (2023). Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis. Immunology, 170(3), 439-451. https://doi.org/10.1111/imm.13683
Vancouver
Wu J, Liu C, Wang T, Liu H, Wei B. Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis. Immunology. 2023;170(3):439-451. doi:10.1111/imm.13683
BibTeX
@article{Wu2023,
author = {Wu, Jingjing and Liu, Chang and Wang, Tao and Liu, Hua and Wei, Bin},
title = {Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis},
journal = {Immunology},
year = {2023},
volume = {170},
number = {3},
pages = {439--451},
doi = {10.1111/imm.13683}
}
EUVIMED